These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 32752583)

  • 1. [Immunotherapy Advances in Small Cell Lung Cancer].
    Xu Y; Zhan P; Song Y
    Zhongguo Fei Ai Za Zhi; 2020 Nov; 23(11):989-998. PubMed ID: 32752583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical Development of Immunotherapy for Small Cell Lung Cancer].
    Yu T; Zhong D
    Zhongguo Fei Ai Za Zhi; 2018 Dec; 21(12):918-923. PubMed ID: 30591100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of immunotherapy in small cell lung cancer.
    Calles A; Aguado G; Sandoval C; Álvarez R
    Clin Transl Oncol; 2019 Aug; 21(8):961-976. PubMed ID: 30637710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy in Lung Cancer.
    Castellanos EH; Horn L
    Cancer Treat Res; 2016; 170():203-23. PubMed ID: 27535396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer.
    Tian Y; Zhai X; Han A; Zhu H; Yu J
    J Hematol Oncol; 2019 Jun; 12(1):67. PubMed ID: 31253167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer.
    Konala VM; Madhira BR; Ashraf S; Graziano S
    Oncology; 2020; 98(11):749-754. PubMed ID: 32663833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Advances and Future Strategies for Immune-Checkpoint Inhibition in Small-Cell Lung Cancer.
    Chae YK; Pan A; Davis AA; Mohindra N; Matsangou M; Villaflor V; Giles F
    Clin Lung Cancer; 2017 Mar; 18(2):132-140. PubMed ID: 27520630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of 
Small Cell Lung Cancer].
    Huang B; Duan Y
    Zhongguo Fei Ai Za Zhi; 2019 Apr; 22(4):239-244. PubMed ID: 31014443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy versus standard chemotherapy for treatment of extensive-stage small-cell lung cancer: a systematic review.
    Liu X; Xing H; Zhang H; Liu H; Chen J
    Immunotherapy; 2021 Aug; 13(12):989-1000. PubMed ID: 34114477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Finally, after decades, immune checkpoint inhibitors dethroned the standard of care of small-cell lung cancer.
    Saleh K; Khalife-Saleh N; Kourie HR
    Immunotherapy; 2019 Apr; 11(6):457-460. PubMed ID: 30860440
    [No Abstract]   [Full Text] [Related]  

  • 11. The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer.
    Horn L; Reck M; Spigel DR
    Oncologist; 2016 Aug; 21(8):910-21. PubMed ID: 27354668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Progress of PD-1/PD-L1 inhibitors in the treatment of small-cell lung cancer].
    Zhang SY; Wang Y
    Zhonghua Zhong Liu Za Zhi; 2021 Jan; 43(1):98-103. PubMed ID: 33472320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opportunities and obstacles of targeted therapy and immunotherapy in small cell lung cancer.
    Yu L; Lai Q; Gou L; Feng J; Yang J
    J Drug Target; 2021 Jan; 29(1):1-11. PubMed ID: 32700566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers.
    Gelsomino F; Lamberti G; Parisi C; Casolari L; Melotti B; Sperandi F; Ardizzoni A
    Cancer Treat Rev; 2019 Sep; 79():101887. PubMed ID: 31491661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new hope: the immunotherapy in small cell lung cancer.
    Li Q; Yuan D; Ma C; Liu Y; Ma L; Lv T; Song Y
    Neoplasma; 2016; 63(3):342-50. PubMed ID: 26925794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Immunotherapy in Extensive Stage Small-Cell Lung Cancer: A Review of the Literature.
    Tsiouprou I; Zaharias A; Spyratos D
    Can Respir J; 2019; 2019():6860432. PubMed ID: 31781314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches.
    Spigel DR; Socinski MA
    J Thorac Oncol; 2013 May; 8(5):587-98. PubMed ID: 23546044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Advances of immunotherapy in small cell lung cancer].
    Liu J; Zhang S; Li H; Cheng Y
    Zhongguo Fei Ai Za Zhi; 2014 Jun; 17(6):474-80. PubMed ID: 24949688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue and circulating biomarkers of benefit to immunotherapy in extensive-stage small cell lung cancer patients.
    Lorenzi M; Resi MV; Bonanno L; Frega S; Dal Maso A; Ferro A; Guarneri V; Pasello G
    Front Immunol; 2024; 15():1308109. PubMed ID: 38348046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy for small cell lung cancer: mechanisms of resistance.
    Hamilton G; Rath B
    Expert Opin Biol Ther; 2019 May; 19(5):423-432. PubMed ID: 30855195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.